期刊文献+

HPLC法同时测定肝微粒体中右美沙芬和咪达唑仑的代谢速率

Simultaneous determination of dextromethorphan and midazolam in rat liver microsome by HPLC
下载PDF
导出
摘要 目的:建立大鼠肝微粒体中右美沙芬和咪达唑仑测定的高效液相色谱法,并考察其在大鼠肝微粒体内的代谢速率.方法:以地西泮为内标,样品在肝微粒内孵育,用乙腈沉淀蛋白浓集后进样分析.流动相:乙腈-磷酸盐缓冲液(0.01mol L-1 K2HPO4-0.5%三乙胺,HCl调PH至7.0)=40:60;检测波长:202 nm;柱温:30℃.结果:该方法能够满足肝微粒体内右美沙芬和咪达唑仑的含量测定要求.DM和MD的代谢速率分别是0.4406±0.066 nmol mg-1.min-1和0.7582±0.018 nmol mg-1.min-1.结论:本方法简单、专属性好、准确度高、灵敏度好,可用于肝微粒中右美沙芬和咪达唑仑的代谢研究. Objective:To develop an HPLC method for the determination of dextromethorphan and midazolam,and investigate their metabolic velocity in rat liver microsome.Method:After being incubated in liver microsome,dextromethorphan and midazolam are extracted with acetonitrile.The organic solution is evaporated and concentrated by mobile phase for analysis.The chromatographic conditions are adopted as follows:mobile phase is acetonitrile-phosphate buffer(0.01 moloL-1 K2HPO4-0.5% triethylamine,add HCl to adjust the pH value of 7.0) = 40:60;detection wavelength is 202 nm;column temperature is 30 ℃.Result:This method is fully validated and the metabolic velocity of dextromethorphan and midazolam are 0.4406±0.066 nmolomg-1·min-1 and 0.7582±0.018 nmolomg-1·min-1.Conclusion:The method is simple,specifical,accurate,precise and sensitive.The successful application demonstrates that the developed method could be readily used in the study of the metabolism of dextromethorphan and midazolam in liver microsome.
出处 《西南民族大学学报(自然科学版)》 CAS 2011年第5期779-782,共4页 Journal of Southwest Minzu University(Natural Science Edition)
基金 成都医学院校级自然基金项目(2008Z025)
关键词 高效液相色谱法 右美沙芬 咪达唑仑 肝微粒体 HPLC dextromethorphan midazolam liver microsome
  • 相关文献

参考文献6

  • 1周宏濒.遗传药理学[M].北京:科学出版社,2001:361-362.
  • 2FORRESTER LM, HENDERSON CJ, GLANCEY M J, et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics[J]. Biochem J, 1992, 281:359-368.
  • 3余奇,康新,郭澄.人体内细胞色素P450 3A探针的研究进展[J].药学服务与研究,2008,8(3):212-215. 被引量:1
  • 4VON BC, GMTH CG, JANSSON H, et al. Drug metabolism in human liver in vitro: establishment of a human liver bank[J]. Clin Pharmacol Ther, 1980,27:711.
  • 5ZHANG W, HAN FT, GUO P, et al. Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS-A high throughput approach to evaluate drug-drug interactions[J]. Journal of Chromatography B, 2010, 878:1169-1177.
  • 6KUMARA A, MANNA H J, REMMEL RP. Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma[J]. Journal of Chromatography B, 2007,853: 287-293.

二级参考文献28

  • 1Du Jing, Yu Lan, Wang Lei, et al. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations[J]. Clin Chim Acta, 2007, 383(1-2): 172-174.
  • 2Streetman D S, Bertino J S Jr, Nafziger A N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-viva cytochrome P450 phenotyping probes[J]. Pharmaeogenetics, 2000, 10(3): 187-216.
  • 3Gorski J C, Hall S D, Jones D R,et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily[J]. Biochem Pharmacol, 1994, 47(9): 1643-1653.
  • 4Lee J I, Chaves-Gnecco D, Amico J A,et al. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping[J]. Clin Pharmacol Ther, 2002,72(6): 718-728.
  • 5Kim R B, Wandel C, Leake B,et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glyeoprotein[J].Pharm Res, 1999, 16(3): 408-414.
  • 6Thummel K E, Shen D D, Podoll T D,et al. Use of midazolam as a human cytochrome P450 3A probe: Ⅰ.In vitro-in vivo correlations in liver transplant patients[J]. Exp Ther, 1994, 271(1): 549-556.
  • 7Ryu J Y, Song I S, Sunwoo Y E, et al. Development of the "inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo [J]. Clin Pharmacol Ther, 2007, 82(5) :531-540.
  • 8Lin Y S, Lockwood G F, Graham M A,et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration[J].Pharmacogenetics, 2001, 11(9):781-791.
  • 9Lee L S, Bertino J S Jr, Nafziger A N. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomar-kerof CYP3A activity[J]. J Clin Pharmacol, 2006, 46(2): 229-234.
  • 10Galteau M M, Shamsa F. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals[J]. Eur J Clin Pharmacol, 2003, 59(10): 713-733.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部